BioLineRx (NASDAQ:BLRX) Shares Pass Above 200-Day Moving Average – Here’s Why

Posted by ABMN Staff on Jul 9th, 2026

BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.87 and traded as high as $3.05. BioLineRx shares last traded at $3.01, with a volume of 221,991 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioLineRx in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Read Our Latest Research Report on BLRX

BioLineRx Price Performance

The firm has a market cap of $13.15 million, a price-to-earnings ratio of -1.57 and a beta of 1.55. The company has a current ratio of 1.58, a quick ratio of 1.43 and a debt-to-equity ratio of 0.16. The stock’s fifty day moving average price is $3.16 and its 200-day moving average price is $2.87.

BioLineRx (NASDAQ:BLRX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.68. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.34 million.

BioLineRx Company Profile

(Get Free Report)

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.